

(95% CI 4.7, 10.2). The majority of incident STIs were new infections: 79 of 119 CT infections, 41 of 48 GC infections, and 23 of 29 TV infections diagnosed were in women who did not have these infections at enrollment. The majority of these infections were asymptomatic.

**Conclusion** The prevalence and incidence of treatable STIs were high among young African women initiating PrEP. Diagnostic STI testing is important and innovative strategies that reduce STI acquisition, complications, and their potential impact on future fertility, need evaluation within the context of PrEP services where currently syndromic STI management is the standard of care.

**Disclosure** No significant relationships.

#### 010.4 SCALING UP HCV SCREENING AND TREATMENT FOR ELIMINATING HCV AMONG MSM IN UK IN THE ERA OF HIV PRE-EXPOSURE PROPHYLAXIS

<sup>1</sup>Louis MacGregor\*, <sup>2</sup>Monica Desai, <sup>3</sup>Natasha Martin, <sup>1</sup>Jane Nicholls, <sup>4</sup>Ford Hickson, <sup>5</sup>Peter Weatherburn, <sup>6</sup>Matthew Hickman, <sup>6</sup>Peter Vickerman. <sup>1</sup>University of Bristol, Bristol, UK; <sup>2</sup>University of Manchester, Manchester, UK; <sup>3</sup>University of California San Diego, San Diego, USA; <sup>4</sup>London School of Hygiene and Tropical Medicine, London, UK; <sup>5</sup>London School of Hygiene and Tropical Medicine, Sigma Research, London, UK; <sup>6</sup>University of Bristol, Population Health Sciences, Bristol, UK

10.1136/sextrans-2019-sti.161

**Background** Routine HIV pre-exposure prophylaxis (PrEP) and HIV care appointments provide opportunities for screening men who have sex with men (MSM) for hepatitis C virus infection (HCV). However, levels of screening required for achieving the WHO elimination target of reducing HCV incidence by 90% by 2030 among all MSM are unknown.

**Methods** An HCV/HIV transmission model was calibrated to UK prevalence of HIV (5.9%) and chronic HCV infection among HIV-positive MSM (10.0%). Assuming 12.5% coverage of PrEP among HIV-negative MSM, we evaluated the impact on HCV incidence (2018–2030) of HCV screening every 12/6/3-months (and completing treatment within 6 months of diagnosis) in PrEP users and/or HIV-diagnosed MSM. We then estimated the additional screening required among HIV-negative non-PrEP users to achieve a 90% reduction in overall incidence by 2025/2030. The effect of a 50% reduction in condom use among PrEP users (risk compensation) was estimated.

**Results** Without risk compensation, PrEP scale-up decreases HCV incidence by 9.5% by 2030, whereas it increases by 26.5% with risk compensation. Screening and treating PrEP users for HCV every 12/6/3-months decreases HCV incidence by 41/46/48%, respectively, increasing to 74/81/83% if HIV-diagnosed MSM are also screened at the same frequencies. Risk compensation reduces these latter projections by <5%. To achieve a 90% reduction in HCV incidence by 2030 (values in bracket are with risk compensation), HIV-negative MSM not on PrEP require screening every 5.2 (4.5) years if MSM on PrEP and HIV-diagnosed MSM are screened every 6-months, decreasing to every 2.6 (2.3) years for the 2025 target. For 25% PrEP coverage, then the 2030 HCV

elimination target may be reached without screening HIV-negative MSM not on PrEP.

**Conclusion** Increased screening of all MSM (particularly HIV-diagnosed MSM and MSM on PrEP) is required to achieve the WHO HCV-elimination targets for MSM in the UK.

**Disclosure** No significant relationships.

#### 010.5 PATTERNS OF HIV PRE-EXPOSURE PROPHYLAXIS CARE ONE YEAR AFTER INITIATING PREP, BALTIMORE CITY, MARYLAND 2015–2018

<sup>1</sup>Linxuan Wu\*, <sup>1</sup>Christina Schumacher, <sup>2</sup>Aruna Chandran, <sup>3</sup>Errol Fields, <sup>4</sup>Maisha Davis, <sup>5</sup>Patrick Ryscavage, <sup>6</sup>Joyce Jones, <sup>7</sup>Kathleen Page, <sup>8</sup>Renata Arrington-Sanders, <sup>9</sup>Vicki Tepper, <sup>10</sup>Jason Farley, <sup>11</sup>Adena Greenbaum, <sup>3</sup>Jacky Jennings. <sup>1</sup>Johns Hopkins School of Medicine, Center for Child And Community Health Research, Baltimore, USA; <sup>2</sup>Johns Hopkins University School of Medicine, Epidemiology, Baltimore, USA; <sup>3</sup>Johns Hopkins University School of Medicine, Center for Child and Community Health Research (CCHR), Baltimore, USA; <sup>4</sup>Chase Brexton Health Care, Baltimore, USA; <sup>5</sup>University of Maryland Midtown Campus, Division Of Infectious Diseases, Baltimore, USA; <sup>6</sup>Johns Hopkins University School of Medicine, The John G. Bartlett Specialty Practice, Baltimore, USA; <sup>7</sup>Baltimore City Health Department, Sexual Health/STD Clinics, Baltimore, USA; <sup>8</sup>The Johns Hopkins Hospital, Harriet Lane Clinic, Baltimore, USA; <sup>9</sup>University of Maryland School of Medicine, Department of Pediatrics, Baltimore, USA; <sup>10</sup>The Johns Hopkins University School of Nursing., Reach Initiative, Baltimore, USA; <sup>11</sup>Baltimore City Health Department, Baltimore, USA

10.1136/sextrans-2019-sti.162

**Background** Persistent HIV pre-exposure prophylaxis (PrEP) use is critical to preventing HIV acquisition. U.S. Centers for Disease Control and Prevention (CDC) recommends quarterly clinical evaluation for individuals using PrEP. Individual-level adherence to quarterly PrEP-care visits is largely unknown. Our objective was to describe patterns of quarterly PrEP-care visit attendance among individuals enrolled in a large demonstration project to increase PrEP delivery in Baltimore City, Maryland.

**Methods** The project was a collaboration between a city health department, an academic evaluation partner, 6 clinical sites and one community based organization (CBO). Demographic and quarterly PrEP-care visit information from individuals initiating PrEP between October 1, 2015 and August 31, 2017 was abstracted from medical records using standardized forms. Participants were followed for one year. PrEP-care was categorized as ‘Persistent’ (attending all quarterly PrEP-care visits), ‘Episodic’ (missing  $\geq 1$  PrEP-care visit and re-engaging PrEP-care visit), or ‘Discontinued’ (lost to follow-up after missing  $\geq 1$  PrEP-care visit).

**Results** During the study period, 333 individuals initiated PrEP, among whom 52.9% (176) were Black/African-American, 82.3% (274) cisgender male, 73.6% (245) men who have sex with men (MSM), and 47.7% (159) aged 25–24 years. 9.0% (30), 40.5% (135), and 50.5% (168) were persistent, episodic and discontinued PrEP-care users, respectively. Over half (51.1%, 69/135) of episodic users missed the first quarterly visit; mean time to PrEP re-engaging was 6.3 months (SD: 2.18). About half (45.2%, 76/168) of those discontinuing PrEP-care did so within 3-months.

**Conclusion** Over one year, < 10% of individuals initiating PrEP were persistently in PrEP-care, and half discontinued PrEP-care completely. This suggests PrEP’s effectiveness in